Reyon Biotech: It is expected that the net profit in the first half of the year will increase by 30%-60% year-on-year.

Rhein Biotech announced that it is expected to achieve a net profit of 49.543-60.976 million yuan in the first half of 2026, an increase of 30%-60% compared to the previous year. The main reasons are that the company continues to improve product quality, enhance customer stickiness, and drive steady growth in operating income; on the other hand, the company continues to optimize product structure, resulting in a certain repair of the comprehensive gross profit margin compared to the same period last year. The simultaneous growth in income and improvement in gross profit drive the company's performance to achieve high growth during the reporting period.